Al-Litani, Karen;
Ali, Tariq;
Robles Martinez, Pamela;
Buanz, Asma;
(2023)
3D printed implantable drug delivery devices for women’s health: Formulation challenges and regulatory perspective.
Advanced Drug Delivery Reviews
, Article 114859. 10.1016/j.addr.2023.114859.
(In press).
Preview |
PDF
1-s2.0-S0169409X23001746-main.pdf - Accepted Version Download (2MB) | Preview |
Abstract
Modern pharmaceutical interventions are shifting from traditional “one-size-fits-all” approaches toward tailored therapies. Following the regulatory approval of Spritam®, the first marketed drug manufactured using three-dimensional printing (3DP) technologies, there is a precedence set for the use of 3DP in the manufacture of pharmaceutical products. The involvement of 3DP technologies in pharmaceutical research has demonstrated its capabilities in enabling the customisation of characteristics such as drug dosing, release characteristics and product designs on an individualised basis. Nonetheless, research into 3DP implantable drug delivery devices lags behind that for oral devices, cell-based therapies and tissue engineering applications. The recent efforts and initiatives to address the disparity in women’s health is overdue but should provide a drive for more research into this area, especially using new and emerging technologies as 3DP. Therefore, the focus of this review has been placed on the unique opportunity of formulating personalised implantable drug delivery systems using 3DP for women’s health applications, particularly passive implants. An evaluation of the current landscape and key formulation challenges for achieving this is provided supplemented with critical insight into the current global regulatory status and its outlook.
| Type: | Article |
|---|---|
| Title: | 3D printed implantable drug delivery devices for women’s health: Formulation challenges and regulatory perspective |
| Open access status: | An open access version is available from UCL Discovery |
| DOI: | 10.1016/j.addr.2023.114859 |
| Publisher version: | https://doi.org/10.1016/j.addr.2023.114859 |
| Language: | English |
| Additional information: | This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third-party material in this article are included in the Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ |
| Keywords: | Additive manufacturing, Localised therapy, biodegradable, non-biodegradable, women’s health, progesterone, estrogen, intrauterine, obstetrics and gynaecology |
| UCL classification: | UCL UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Life Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Life Sciences > UCL School of Pharmacy UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Life Sciences > UCL School of Pharmacy > Pharmaceutics |
| URI: | https://discovery-pp.ucl.ac.uk/id/eprint/10169619 |
Archive Staff Only
 |
View Item |
